U.S. Markets close in 3 hrs 48 mins
  • S&P 500

    +1.48 (+0.04%)
  • Dow 30

    -29.89 (-0.10%)
  • Nasdaq

    -4.72 (-0.04%)
  • Russell 2000

    -7.43 (-0.40%)
  • Crude Oil

    +1.09 (+2.45%)
  • Gold

    +10.40 (+0.57%)
  • Silver

    -0.05 (-0.19%)

    +0.0018 (+0.1452%)
  • 10-Yr Bond

    +0.0190 (+2.03%)
  • Vix

    -0.07 (-0.34%)

    -0.0071 (-0.5274%)

    +0.17 (+0.1668%)

    -116.29 (-0.61%)
  • CMC Crypto 200

    +4.59 (+1.26%)
  • FTSE 100

    +78.6602 (+1.23%)
  • Nikkei 225

    +13.44 (+0.05%)

Coloplast (CPH:COLO B) Seems To Use Debt Rather Sparingly

Simply Wall St

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk. It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. As with many other companies Coloplast A/S (CPH:COLO B) makes use of debt. But the more important question is: how much risk is that debt creating?

When Is Debt Dangerous?

Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. By replacing dilution, though, debt can be an extremely good tool for businesses that need capital to invest in growth at high rates of return. When we think about a company's use of debt, we first look at cash and debt together.

See our latest analysis for Coloplast

What Is Coloplast's Net Debt?

As you can see below, Coloplast had ø2.84b of debt at June 2019, down from ø3.07b a year prior. On the flip side, it has ø755.0m in cash leading to net debt of about ø2.09b.

CPSE:COLO B Historical Debt, September 29th 2019
CPSE:COLO B Historical Debt, September 29th 2019

How Healthy Is Coloplast's Balance Sheet?

According to the last reported balance sheet, Coloplast had liabilities of ø5.96b due within 12 months, and liabilities of ø657.0m due beyond 12 months. On the other hand, it had cash of ø755.0m and ø3.48b worth of receivables due within a year. So it has liabilities totalling ø2.37b more than its cash and near-term receivables, combined.

Having regard to Coloplast's size, it seems that its liquid assets are well balanced with its total liabilities. So it's very unlikely that the ø176.1b company is short on cash, but still worth keeping an eye on the balance sheet. But either way, Coloplast has virtually no net debt, so it's fair to say it does not have a heavy debt load!

We use two main ratios to inform us about debt levels relative to earnings. The first is net debt divided by earnings before interest, tax, depreciation, and amortization (EBITDA), while the second is how many times its earnings before interest and tax (EBIT) covers its interest expense (or its interest cover, for short). This way, we consider both the absolute quantum of the debt, as well as the interest rates paid on it.

Coloplast has a low debt to EBITDA ratio of only 0.34. But the really cool thing is that it actually managed to receive more interest than it paid, over the last year. So it's fair to say it can handle debt like a hot shot teppanyaki chef handles cooking. Also good is that Coloplast grew its EBIT at 10% over the last year, further increasing its ability to manage debt. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine Coloplast's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. So we clearly need to look at whether that EBIT is leading to corresponding free cash flow. During the last three years, Coloplast produced sturdy free cash flow equating to 61% of its EBIT, about what we'd expect. This free cash flow puts the company in a good position to pay down debt, when appropriate.

Our View

The good news is that Coloplast's demonstrated ability to cover its interest expense with its EBIT delights us like a fluffy puppy does a toddler. And the good news does not stop there, as its net debt to EBITDA also supports that impression! We would also note that Medical Equipment industry companies like Coloplast commonly do use debt without problems. Looking at the bigger picture, we think Coloplast's use of debt seems quite reasonable and we're not concerned about it. After all, sensible leverage can boost returns on equity. Over time, share prices tend to follow earnings per share, so if you're interested in Coloplast, you may well want to click here to check an interactive graph of its earnings per share history.

When all is said and done, sometimes its easier to focus on companies that don't even need debt. Readers can access a list of growth stocks with zero net debt 100% free, right now.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.